IMMNOV.ST - Immunovia AB (publ)

Stockholm - Stockholm Real Time Price. Currency in SEK
201.50
-43.50 (-17.76%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close245.00
Open185.20
Bid201.50 x 0
Ask202.00 x 0
Day's Range180.80 - 210.00
52 Week Range75.50 - 273.50
Volume659,409
Avg. Volume57,116
Market Cap3.925B
Beta2.49
PE Ratio (TTM)N/A
EPS (TTM)-3.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire3 days ago

    Journal of Clinical Oncology Publishes That IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy

    LUND, Sweden , Aug. 15, 2018 /PRNewswire/ --Immunovia AB announced today that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical validation study ...

  • PR Newswire9 days ago

    Immunovia`s Blood-based IMMray™ Biomarker Array Provides Highly Accurate Diagnosis of non-small Cell Lung Cancer in a New Collaborative Study

    LUND, Sweden, Aug 9, 2018 /PRNewswire/ -- Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray™ ...

  • PR Newswire15 days ago

    Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test

    Immunovia AB today announced that the Karolinska Institutet is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, the study will analyze more than thousand individuals over three years across sites in Sweden, the US and Europe already offering FPC screening programs. The aim is to improve the outcome for the cancer patients and to prove the overall healthcare benefits of testing persons with heredity for pancreatic cancer.

  • PR Newswire15 days ago

    Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test

    Immunovia AB today announced that the Karolinska Institutet is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, the study will analyze more than thousand individuals over three years across sites in Sweden, the US and Europe already offering FPC screening programs. The aim is to improve the outcome for the cancer patients and to prove the overall healthcare benefits of testing persons with heredity for pancreatic cancer.

  • PR Newswire2 months ago

    Immunovia has Completed a Directed Share Issue of Approximately SEK 324 Million

    Immunovia AB (publ) ("Immunovia" or the "Company") today announces that the Company has successfully completed a directed share issue which will provide the Company with a gross proceed of approximately SEK 324 million. The board of directors of Immunovia has, based on the authorization granted by the annual general meeting May 3, 2018, and as announced in the Company's press release on May 7, 2018, resolved on a directed share issue of 2,162,794 new shares at a subscription price of SEK 150 per share (the "Share Issue"), which means that the Company will receive proceeds of approximately SEK 324 million before transaction costs.

  • PR Newswire2 months ago

    Immunovia Announces its Intent to Carry out a Directed Share Issue

    Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to execute a directed share issue to Swedish and international qualified and/or institutional investors (the "Share Issue"). The contemplated Share Issue will be carried out under the authorization received from the annual general meeting on May 3, 2018 and may entail an issue of a maximum number of shares corresponding to a maximum of 20 percent of the number of shares in the Company as of the day of this announcement, i.e. The subscription price and the total number of new shares in the Share Issue will be determined through an accelerated bookbuilding procedure (the "Bookbuilding Procedure").

  • PR Newswire3 months ago

    Linköping University Hospital Second Swedish Site in Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

    Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer. LUND and LINKÖPING, Sweden, May 22, 2018 /PRNewswire/ -- Immunovia AB today announced that Linköping University Hospital is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, the study will analyze more than thousand individuals over three years across sites in Sweden, the US and Europe already offering FPC screening programs.

  • PR Newswire3 months ago

    Linköping University Hospital Second Swedish Site in Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

    Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer. LUND and LINKÖPING, Sweden , May 22, 2018 /PRNewswire/ -- Immunovia AB today announced that ...

  • ACCESSWIRE5 months ago

    Edison Issues Outlook on Immunovia (IMMUNOV)

    LONDON, UK / ACCESSWIRE / March 22, 2018 / Immunovia (STOCKHOLM: IMMNOV) is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory ...

  • PR Newswire5 months ago

    Immunovia Announces Financial Targets

    The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company's goal is to reach SEK 250-300 million in turnover in 2021 based on "self-pay"-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US. Immunovia performs clinical validation studies for the commercialization of IMMray™ PanCan-d, which may be the first blood-based test for early diagnosis of pancreatic cancer.

  • PR Newswire5 months ago

    Immunovia Announces Financial Targets

    The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company's goal is to reach SEK 250-300 million in turnover in 2021 based on "self-pay"-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US. Immunovia performs clinical validation studies for the commercialization of IMMray™ PanCan-d, which may be the first blood-based test for early diagnosis of pancreatic cancer.